Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction

@article{Granfors2004FluvoxamineDI,
  title={Fluvoxamine Drastically Increases Concentrations and Effects of Tizanidine: A Potentially Hazardous Interaction},
  author={M. Granfors and J. Backman and M. Neuvonen and J. Ahonen and P. Neuvonen},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2004},
  volume={75}
}
Our objective was to study the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of tizanidine, a centrally acting skeletal muscle relaxant. 
Ciprofloxacin greatly increases concentrations and cypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2–mediated presystemic metabolism
TLDR
The objective was to study the extent and mechanism of a possible interaction of ciprofloxacin with tizanidine, a centrally acting skeletal muscle relaxant, which has a low oral bioavailability. Expand
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients
Aims:  Tizanidine, one of the few oral antispastic therapies approved for use in the USA, has a narrow therapeutic index that can often make optimal patient dosing difficult. We surveyed theExpand
Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2
TLDR
The effect of combined OCs, containing ethinyl estradiol and gestodene, on CYP1A2 activity, as well as their interaction potential with tizanidine, is studied. Expand
Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine
Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
TLDR
Rofecoxib is a potent inhibitor of CYP1A2 and it greatly increases the plasma concentrations and adverse effects of tizanidine, raising concerns about interactions between rofecoxIB and other CYP 1A2 substrate and inhibitor drugs. Expand
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine
TLDR
The inducibility of CYP1A2-mediated presystemic (tizanidine, caffeine) and systemic metabolism by rifampicin is weak at the most, compared to CYP3A4 substrate drugs, which are much less susceptible to drug interactions caused by enzyme inducers of the rifampsicin type. Expand
Co‐Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine‐Associated Hypotension: A Retrospective Cohort Study
TLDR
CYP1A2 inhibition increases the risk of hypotensive episodes associated with the use of tizanidine in routine clinical practice, and a sensitivity analysis that defined hypotension as SBP < 90 mmHg also yielded higher rates of hypotension among patients prescribed tIZanidine. Expand
Effects of Mexiletine, a CYP1A2 Inhibitor, on Tizanidine Pharmacokinetics and Pharmacodynamics
TLDR
It is suggested that coadministration of mexiletine increased blood tizanidine concentrations and enhanced tIZanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms. Expand
Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption.
TLDR
The physiologically based pharmacokinetic (PBPK) modeling platform Simcyp® was used to evaluate the impact of CYP1A2 modulation on tizanidine exposure through drug-drug interactions (DDIs) and host-dependent habits (cigarette smoking). Expand
Drug interaction of tizanidine and fluvoxamine
TLDR
It was important to establish that the increased rate of diarrhea seen with oxaliplatin–5-FU compared with the rate for 5-FU alone is not simply a result of reduced 4-FU clearance, and there is clearly a role for both types of study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
Our objective was to study the effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride, a new sulfonylurea antidiabetic drug.
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Midazolam is a short‐acting benzodiazepine that is metabolized by CYP3A enzymes. Rifampin is a potent enzyme inducer that may seriously interact with some substrates of CYP3A4.
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans
TLDR
The aim of this study was to examine the influence of fluvoxamine administration on the disposition kinetics of single‐dose tacrine administration. Expand
Fluvoxamine‐theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2
TLDR
In vitro and in vivo inhibition potencies of fluvoxamine toward CYP1A2 are compared with an approach based on inhibition constants (Ki) determined in vivo and in vitro. Expand
Low daily 10‐mg and 20‐mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
TLDR
Whether nontherapeutic doses of fluvoxamine inhibit CYP1A2 but possibly not CYP2C19 is investigated. Expand
The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone
TLDR
Fluvoxamine moderately increased plasma buspirone concentrations and decreased the production of the active 1-PP metabolite of buspir one, and this pharmacokinetic interaction was not associated with impairment of psychomotor performance and it is probably of limited clinical significance. Expand
The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.
TLDR
Concomitant use of fluvoxamine and CYP3A4 inhibitor erythromycin further increases plasma ropivacaine concentration by decreasing its clearance and inhibition of CYP1A2 by fluVoxamine considerably reduces elimination of ropvacaine. Expand
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole
TLDR
The findings suggest that selegiline is not susceptible to interaction with CYP3A4 inhibitors, and shows no inhibitory effect on the biotransformation of se LEGiline to desmethylselegilines and l-methamphetamine by human liver microsomes. Expand
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.
TLDR
CYP1A2 is primarily responsible for the metabolism of tizanidine, but other recombinant CYPs had little metabolic capacity for the drug and CYP1A1 inhibitors may inhibit its metabolism also in vivo. Expand
An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe
TLDR
All three commercially marketed doses of rofecoxib were found to slow the clearance of theophylline with no detectable effect on absorption as well as point estimates of CL/F found to be in agreement with those derived from AUC. Expand
...
1
2
3
...